Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
Table 2
Peripheral blood CD34+ cell and WBC count kinetics in response to plerixafor salvage in patients with extremely low baseline CD34+ cell counts.
PB counts (/μL)
Baseline
Post P dose no. 1
Post P dose no. 2
Post P dose no. 3
Post P dose no. 4
Post P dose no. 5
Post P dose no. 6
Post P dose no. 7
Post P dose no. 8
Patient #1
WBC
28.5
25.8
24.7
27.3
43.3
CD34+
1
1
1
2
4
Patient #2
WBC
14
22.6
26.2
28.9
31.3
34.1
38.4
46.1
CD34+
1
2
2
4
4
6
7
11
Patient #3
WBC
4.1
10.6
14.7
14.8
17.1
18.6
20
22.7
27
CD34+
0
3
4
3
3
8
9
6
12
Patient #4
WBC
19.4
51.6
60.8
58.8
58.1
66.9
80.1
CD34+
0
3
2
4
4
13
13
P = plerixafor; PB = peripheral blood; WBC = white blood cell count.
